{"id":"lorajmine","rwe":[],"tags":[{"label":"lorajmine","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"C01BA12","category":"atc"},{"label":"Active","category":"status"},{"label":"Anti-Arrhythmia Agents","category":"pharmacology"},{"label":"Cardiovascular Agents","category":"pharmacology"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":["lorajmine hydrochloride","lorajmine","lorajmine HCl"],"offLabel":[],"synonyms":["lorajmine hydrochloride","lorajmine","lorajmine HCl"],"timeline":[],"approvals":[],"ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"lorajmine","explanation":"Imagine your body's cells have locks on them, and lorajmine is a key that fits into one of those locks. When it binds to the lock, it can affect how the cell works, but the details of how it does this are not yet clear.","oneSentence":"Lorajmine is thought to work by interacting with a specific biological target, but the exact mechanism is not well understood.","technicalDetail":"Lorajmine is a small molecule that binds to a specific protein or receptor, potentially altering its function and leading to therapeutic effects."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1604","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=LORAJMINE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=LORAJMINE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T12:24:50.148248","biosimilars":[],"competitors":[{"drugName":"quinidine","drugSlug":"quinidine","fdaApproval":"1950-07-12","genericCount":35,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"procainamide","drugSlug":"procainamide","fdaApproval":"1950-06-02","genericCount":26,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"disopyramide","drugSlug":"disopyramide","fdaApproval":"1977-09-01","genericCount":10,"patentStatus":"Off-patent — generic available","relationship":"same-class"}],"genericName":"lorajmine","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"quinidine","brandName":"quinidine","genericName":"quinidine","approvalYear":"1950","relationship":"same-class"},{"drugId":"procainamide","brandName":"procainamide","genericName":"procainamide","approvalYear":"1950","relationship":"same-class"},{"drugId":"disopyramide","brandName":"disopyramide","genericName":"disopyramide","approvalYear":"1977","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT06376552","phase":"","title":"Artificial Intelligence for the Prioritization of Genetic Background in Brugada Syndrome","status":"COMPLETED","sponsor":"IRCCS San Raffaele","startDate":"2018-12-19","conditions":["Brugada Syndrome"],"enrollment":200,"completionDate":"2022-06-06"},{"nctId":"NCT03992677","phase":"","title":"Feasibility of Improving Risk Stratification in Brugada Syndrome","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2017-12-01","conditions":["Brugada Syndrome","Cardiac Arrest","Athletes Heart","Atrial Fibrillation","Ventricular Ectopic Beat"],"enrollment":45,"completionDate":"2022-08-01"},{"nctId":"NCT04580992","phase":"","title":"Defining the Electrocardiographic Effect of Propofol on the Ajmaline Provocation Drug Challenge: A Prospective Trial","status":"UNKNOWN","sponsor":"Universitair Ziekenhuis Brussel","startDate":"2020-11-16","conditions":["Brugada Syndrome","Channelopathies","Ventricular Fibrillation","Cardiac Death"],"enrollment":25,"completionDate":"2022-10-31"},{"nctId":"NCT03524079","phase":"","title":"Right Ventricle Morphology and Hemodynamics in BrS","status":"COMPLETED","sponsor":"IRCCS Policlinico S. Donato","startDate":"2018-04-19","conditions":["Brugada Syndrome"],"enrollment":60,"completionDate":"2019-11-09"},{"nctId":"NCT02933437","phase":"PHASE2","title":"The Response To Ajmaline Provocation in Healthy Subjects","status":"UNKNOWN","sponsor":"St George's, University of London","startDate":"2017-10-22","conditions":["Brugada Syndrome","Sudden Death"],"enrollment":100,"completionDate":"2019-12"},{"nctId":"NCT02052765","phase":"NA","title":"AnalyST & Brugada Syndrome - Feasibility Study","status":"COMPLETED","sponsor":"Abbott Medical Devices","startDate":"2011-02","conditions":["Brugada Syndrome"],"enrollment":16,"completionDate":"2011-05"},{"nctId":"NCT03491475","phase":"","title":"Echocardiography During Ajmaline Test","status":"UNKNOWN","sponsor":"Universitair Ziekenhuis Brussel","startDate":"2018-03-26","conditions":["Brugada Syndrome"],"enrollment":100,"completionDate":"2019-05-31"},{"nctId":"NCT02641431","phase":"NA","title":"Epicardial Ablation in Brugada Syndrome","status":"COMPLETED","sponsor":"IRCCS Policlinico S. Donato","startDate":"2015-11-16","conditions":["Brugada Syndrome"],"enrollment":135,"completionDate":"2016-12-30"},{"nctId":"NCT00702117","phase":"PHASE4","title":"Ajmaline Utilization in the Diagnosis and Treatment of Cardiac Arrhythmias","status":"COMPLETED","sponsor":"Hospital Clinic of Barcelona","startDate":"2008-06","conditions":["Atrial Fibrillation","Tachycardia, Ventricular","Brugada Syndrome"],"enrollment":123,"completionDate":"2010-01"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"F96VX65849","CHEBI":"CHEBI:135646","INN_ID":"3889","UMLSCUI":"C0024001","ChEMBL_ID":"CHEMBL3989762","KEGG_DRUG":"D04774","DRUGBANK_ID":"DB13651","PUBCHEM_CID":"76957773","SECONDARY_CAS_RN":"40819-93-0","MESH_DESCRIPTOR_UI":"D064794"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":5,"therapeuticAreas":["Other"],"atcClassification":{"source":"DrugCentral","atcCode":"C01BA12","allCodes":["C01BA12"]},"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","brandName":"LORAJMINE","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"LORAJMINE, also known as Ajmaline 17-(Chloroacetate) Monohydrochloride, is being studied in clinical trials for various heart conditions, including Brugada Syndrome, Atrial Fibrillation, Tachycardia, Ventricular Fibrillation, and Channelopathies. The exact mechanism of LORAJMINE is not specified in the provided information, but it is being compared to other interventions such as flecainide and ajmaline in these trials.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}